Intervention Review

Molindone for schizophrenia and severe mental illness

  1. Anne-Marie Bagnall1,*,
  2. Mark Fenton2,
  3. Jos Kleijnen3,
  4. Ruth Lewis4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 24 JAN 2007

Assessed as up-to-date: 13 NOV 2006

DOI: 10.1002/14651858.CD002083.pub2

How to Cite

Bagnall AM, Fenton M, Kleijnen J, Lewis R. Molindone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002083. DOI: 10.1002/14651858.CD002083.pub2.

Author Information

  1. 1

    Leeds Metropolitan University, Faculty of Health, Leeds, UK

  2. 2

    James Lind Initiative, Database of Uncertainties about the Effects of Treatments (DUETs), Oxford, UK

  3. 3

    Kleijnen Systematic Reviews Ltd, York, UK

  4. 4

    Cardiff University, Department of General Practice, Wrexham, UK

*Anne-Marie Bagnall, Faculty of Health, Leeds Metropolitan University, Calverley Street, Leeds, LS1 3HE, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JAN 2007


Cited in:


This article has been cited by:

  1. 1
    J. P. Lindenmayer, Frances Alcantara, Anzalee Khan, Michael Ciranni, The Effects of Molindone as a Concomitant Medication on Aggressive Behavior, Clinical Schizophrenia & Related Psychoses, 2010, 3, 4, 193


  2. 2
    C. J. Bushe, A. J. Bradley, S. Doshi, J. Karagianis, Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies, International Journal of Clinical Practice, 2009, 63, 12